Send to

Choose Destination
Osteoporos Int. 2009 May;20(5):703-14. doi: 10.1007/s00198-008-0743-7. Epub 2008 Sep 19.

The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study.

Author information

McMaster University, Hamilton Health Sciences-Chedoke Site, Hamilton, ON, Canada.


Using prospective data from the Canadian Multicentre Osteoporosis Study (CaMos), we compared health utilities index (HUI) scores after 5 years of follow-up among participants (50 years and older) with and without incident clinical fractures. Incident fractures had a negative impact on HUI scores over time.


This study examined change in health-related quality of life (HRQL) in those with and without incident clinical fractures as measured by the HUI.


The study cohort was 4,820 women and 1,783 men (50 years and older) from the CaMos. The HUI was administered at baseline and year 5. Participants were sub-divided into incident fracture groups (hip, rib, spine, forearm, pelvis, other) and were compared with those without these fractures. The effects of both time and fracture type on HUI scores were examined in multivariable regression analyses.


Men and women with hip fractures, compared to those without, had lower HUI measures that ranged from -0.05 to -0.25. Both women and men with spine fractures had significant deficits on the pain attributes (-0.07 to -0.12). In women, self-care (-0.06), mobility and ambulation (-0.05) were also negatively impacted. Women with rib fractures had deficits similar to women with spine fractures, and these effects persisted over time. In men, rib fractures did not significantly affect HUI scores. Pelvic and forearm fractures did not substantially influence HUI scores.


The HUI was a sensitive measure of HRQL change over time. These results will inform economic analyses evaluating osteoporosis therapies.

[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

Alexandra Papaioannou: Consulting Role: Amgen, Eli Lilly, Merck Frosst, Novartis, Proctor & Gamble, sanofi aventis Clinical Trials: Eli Lilly, Merck, Novartis, Proctor & Gamble, sanofi-aventis Jonathan D. Adachi: Consulting Role: Amgen; Astra Zeneca, Eli Lilly; Glaxo-SmithKline; Merck Frosst; Novartis; Proctor & Gamble; Roche; Sanofi Aventis; Servier Clinical Trials: Eli Lilly; GlaxoSmithKline; Merck; Novartis; Pfizer; Proctor & Gamble; sanofi-aventis; Servier; Wyeth-Ayerst Courtney Kennedy: none to declare Andreas Freitag: none to declare John O’Neill: none to declare Margaret Pui: none to declare Colin Webber: none to declare Anjali Pathak: none to declare Suzanne Hansen: none to declare Rosamund Hennessey: none to declare George Ioannidis: none to declare

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center